These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28008590)

  • 1. The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis.
    Fonseca AM; Meinberg MF; Monteiro MV; Roque M; Haddad JM; Castro RA
    Rev Bras Ginecol Obstet; 2016 Nov; 38(11):564-575. PubMed ID: 28008590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
    Farag F; Sakalis VI; Arteaga SM; Sihra N; Karavitakis M; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Groen J; Peyronnet B; Phé V; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK; Carmela Lapitan M; Imran Omar M; Nambiar AK
    Eur Urol; 2023 Sep; 84(3):302-312. PubMed ID: 37331921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
    Vouri SM; Kebodeaux CD; Stranges PM; Teshome BF
    Arch Gerontol Geriatr; 2017; 69():77-96. PubMed ID: 27889591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.
    Stoniute A; Madhuvrata P; Still M; Barron-Millar E; Nabi G; Omar MI
    Cochrane Database Syst Rev; 2023 May; 5(5):CD003781. PubMed ID: 37160401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
    Novara G; Galfano A; Secco S; D'Elia C; Cavalleri S; Ficarra V; Artibani W
    Eur Urol; 2008 Oct; 54(4):740-63. PubMed ID: 18632201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
    Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
    PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
    Lozano-Ortega G; Walker DR; Johnston K; Mickle A; Harrigan S; Rogula B; Kristy RM; Hairston JC; Schermer CR
    Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
    Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
    Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.